- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in the HER2 targeted therapy of gastric cancer
Authors
Keywords
-
Journal
World Journal of Clinical Cases
Volume 3, Issue 1, Pages 42
Publisher
Baishideng Publishing Group Inc.
Online
2015-01-14
DOI
10.12998/wjcc.v3.i1.42
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
- (2014) Y-K Kang et al. BRITISH JOURNAL OF CANCER
- Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
- (2014) Y Kurokawa et al. BRITISH JOURNAL OF CANCER
- Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines
- (2014) Hai Cui et al. Cancer Cell International
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects
- (2014) Jan Trøst Jørgensen WORLD JOURNAL OF GASTROENTEROLOGY
- The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
- (2014) Tasuku Matsuoka et al. Cancers
- HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance
- (2013) W. Q. Sheng et al. ANNALS OF ONCOLOGY
- A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
- (2013) M Yashiro et al. BRITISH JOURNAL OF CANCER
- Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells
- (2013) Yuji Sato et al. CANCER SCIENCE
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines
- (2013) Yukiko Oshima et al. Gastric Cancer
- HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: A prospective cohort observation
- (2013) Miao-Zhen Qiu et al. INTERNATIONAL JOURNAL OF CANCER
- Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
- (2013) Carlos Gomez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
- (2013) Z. A. Wainberg et al. MOLECULAR CANCER THERAPEUTICS
- Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer
- (2013) H-P Kim et al. ONCOGENE
- A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers
- (2013) Jeeyun Lee et al. PLoS One
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- A Large Cohort of Consecutive Patients Confirmed Frequent HER2 Positivity in Gastric Carcinomas with Advanced Stages
- (2012) Junhun Cho et al. ANNALS OF SURGICAL ONCOLOGY
- Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
- (2012) M. Terashima et al. CLINICAL CANCER RESEARCH
- Pertuzumab in HER2-positive breast cancer
- (2012) Mehmet A.N. Sendur et al. CURRENT MEDICAL RESEARCH AND OPINION
- Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry
- (2012) Atsushi Nashimoto et al. Gastric Cancer
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
- (2011) S. Iqbal et al. ANNALS OF ONCOLOGY
- Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays
- (2011) Kab Choong Kim et al. ANNALS OF SURGICAL ONCOLOGY
- Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
- (2011) C Bozzetti et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- (2011) Mark Barok et al. CANCER LETTERS
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
- (2011) Maria D. Begnami et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
- (2011) H.-J. Nam et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the human EGFR family in esophagogastric cancer
- (2011) Alicia Okines et al. Nature Reviews Clinical Oncology
- Anti-HER agents in gastric cancer: from bench to bedside
- (2011) Lorenzo Fornaro et al. Nature Reviews Gastroenterology & Hepatology
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
- (2010) Jaffer A. Ajani et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of HER2 in cancer therapy and targeted drug delivery
- (2010) Wanyi Tai et al. JOURNAL OF CONTROLLED RELEASE
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
- (2009) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
- (2009) Dimitrios H. Roukos ANNALS OF SURGICAL ONCOLOGY
- Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
- (2009) J D Barros-Silva et al. BRITISH JOURNAL OF CANCER
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- HER2 overexpression correlates with survival after curative resection of pancreatic cancer
- (2009) Masahiro Komoto et al. CANCER SCIENCE
- Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity
- (2009) Y. Nagumo et al. MOLECULAR CANCER RESEARCH
- Crosstalk in Met receptor oncogenesis
- (2009) Andrea Z. Lai et al. TRENDS IN CELL BIOLOGY
- Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
- (2009) Xiu Li Zhang et al. WORLD JOURNAL OF SURGERY
- Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
- (2008) M. Dank et al. ANNALS OF ONCOLOGY
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
- (2008) K. Kunii et al. CANCER RESEARCH
- NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
- (2008) S. A. Eccles et al. CANCER RESEARCH
- Heat Shock Protein 90 as a Drug Target: Some Like It Hot
- (2008) U. Banerji CLINICAL CANCER RESEARCH
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started